Jeil Pharmaceutical reorganizes research institute to strengthen new drug development
AI Summary- Jeil Pharmaceutical reorganized its central research institute and appointed Park Jun-seok as head.
- The company consolidated three laboratories into two research centers effective Nov. 1.
- JP9441 remains preclinical before Phase 1, while JP10259 entered preclinical research after candidate selection.